Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation

Open access

Abstract

The glucagon-like peptide receptor (GLP-1R), which is a G-protein coupled receptor (GPCR), signals through both Gαs and Gαq coupled pathways and ERK phosphorylation to stimulate insulin secretion. The aim of this study was to determine molecular details of the effect of small molecule agonists, compounds 2 and B, on GLP-1R mediated cAMP production, intracellular Ca2+ accumulation, ERK phosphorylation and its internalisation. In human GLP-1R (hGLP-1R) expressing cells, compounds 2 and B induced cAMP production but caused no intracellular Ca2+ accumulation, ERK phosphorylation or hGLP-1R internalisation. GLP-1 antagonists Ex(9-39) and JANT-4 and the orthosteric binding site mutation (V36A) in hGLP-1R failed to inhibit compounds 2 and B induced cAMP production, confirming that their binding site distinct from the GLP-1 binding site on GLP-1R. However, K334A mutation of hGLP-1R, which affects Gαs coupling, inhibited GLP-1 as well as compounds 2 and B induced cAMP production, indicating that GLP-1, compounds 2 and B binding induce similar conformational changes in the GLP-1R for Gαs coupling. Additionally, compound 2 or B binding to the hGLP-1R had significantly reduced GLP-1 induced intracellular Ca2+ accumulation, ERK phosphorylation and hGLP-1R internalisation. This study illustrates pharmacology of differential activation of GLP-1R by GLP-1 and compounds 2 and B.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0154229

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Small molecule agonists induce cAMP production but not intracellular Ca2+ accumulation or ERK phosphorylation in hGLP-1R expressing cells. HEK293 cells cotransfected with the hGLP-1R plasmid and the luciferase reporter plasmid for cAMP (pGL4.29-Luc-CRE), intracellular Ca2+ (pGL4.30-Luc-NFAT) or ERK phosphorylation (pGL4.33-Luc-SRE) were stimulated with GLP-1, compound 2 or compound B as indicated to assess cAMP production (A), intracellular Ca2+ accumulation (Ca2+i) (B) and ERK phosphorylation (ERK-p) (C). (D) The EC50 of GLP-1, compounds 2 and B for cAMP production, (Ca2+i) and ERK-p (n.d., not determined). Data normalised to percentage stimulation of GLP-1 and are shown as mean ± SEM, n = 3.
Fig 1 Small molecule agonists induce cAMP production but not intracellular Ca2+ accumulation or ERK phosphorylation in hGLP-1R expressing cells. HEK293 cells cotransfected with the hGLP-1R plasmid and the luciferase reporter plasmid for cAMP (pGL4.29-Luc-CRE), intracellular Ca2+ (pGL4.30-Luc-NFAT) or ERK phosphorylation (pGL4.33-Luc-SRE) were stimulated with GLP-1, compound 2 or compound B as indicated to assess cAMP production (A), intracellular Ca2+ accumulation (Ca2+i) (B) and ERK phosphorylation (ERK-p) (C). (D) The EC50 of GLP-1, compounds 2 and B for cAMP production, (Ca2+i) and ERK-p (n.d., not determined). Data normalised to percentage stimulation of GLP-1 and are shown as mean ± SEM, n = 3.CC BY · PubMed Central
Fig 2 Concentration dependent stimulation of hGLP-1R internalisation by GLP-1, compound 2 and compound B. HEK293 cells expressing the hGLP-1R were stimulated with GLP-1, compound 2 or compound B at the indicated concentration for 60min and hGLP-1R internalisation was assessed by ELISA using the anti-GLP-1R antibody (A) and the VSVG-antibody (B) and by immunofluorescence (D). (C) The EC50 of GLP-1, compounds 2 and B for hGLP-1R internalisation (n.d., not determined). In immunofluorescence, GFP-tagged hGLP-1R (green) and the anti-GLP-1R antibody staining (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean ± SEM, n = 3.
Fig 2 Concentration dependent stimulation of hGLP-1R internalisation by GLP-1, compound 2 and compound B. HEK293 cells expressing the hGLP-1R were stimulated with GLP-1, compound 2 or compound B at the indicated concentration for 60min and hGLP-1R internalisation was assessed by ELISA using the anti-GLP-1R antibody (A) and the VSVG-antibody (B) and by immunofluorescence (D). (C) The EC50 of GLP-1, compounds 2 and B for hGLP-1R internalisation (n.d., not determined). In immunofluorescence, GFP-tagged hGLP-1R (green) and the anti-GLP-1R antibody staining (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean ± SEM, n = 3.CC BY · PubMed Central
Fig 3 Time dependent stimulation of hGLP-1R internalisation by GLP-1, compound 2 and compound B. HEK293 cells expressing the hGLP-1R were stimulated with 100nM GLP-1, 10μM compound 2 or 10μM compound B for the indicated time and assessed hGLP-1R internalisation by ELISA using the anti-GLP-1R antibody (A) and live cell fluorescence imaging (B). Data are mean + SEM, n = 3 (A) or representative of three independent experiments (B).
Fig 3 Time dependent stimulation of hGLP-1R internalisation by GLP-1, compound 2 and compound B. HEK293 cells expressing the hGLP-1R were stimulated with 100nM GLP-1, 10μM compound 2 or 10μM compound B for the indicated time and assessed hGLP-1R internalisation by ELISA using the anti-GLP-1R antibody (A) and live cell fluorescence imaging (B). Data are mean + SEM, n = 3 (A) or representative of three independent experiments (B).CC BY · PubMed Central
Fig 4 Antagonists Ex(9–39) and JANT-4 inhibit cAMP production induced by GLP-1 but not compound 2 or compound B. HEK293 cells cotransfected with the hGLP-1R and the luciferase reporter plasmid for cAMP (pGL4.29-Luc-CRE) were stimulated with GLP-1 (A), compound 2 (B) or compound B (C), as indicated, in the presence of 100nM Ex(9–39) (left panel) or JANT-4 (right panel) to assess cAMP production. (D) The EC50 of GLP-1, compounds 2 and B in the presence or absence of Ex(9–39) or JANT-4 for cAMP production. Data are mean ± SEM, n = 3, *** p <0.001.
Fig 4 Antagonists Ex(9–39) and JANT-4 inhibit cAMP production induced by GLP-1 but not compound 2 or compound B. HEK293 cells cotransfected with the hGLP-1R and the luciferase reporter plasmid for cAMP (pGL4.29-Luc-CRE) were stimulated with GLP-1 (A), compound 2 (B) or compound B (C), as indicated, in the presence of 100nM Ex(9–39) (left panel) or JANT-4 (right panel) to assess cAMP production. (D) The EC50 of GLP-1, compounds 2 and B in the presence or absence of Ex(9–39) or JANT-4 for cAMP production. Data are mean ± SEM, n = 3, *** p <0.001.CC BY · PubMed Central
Fig 5 Concentration dependent stimulation of hGLP-1R internalisation by GLP-1 in the presence of antagonists Ex(9–39) and JANT-4. HEK293 cells expressing the hGLP-1R were stimulated with GLP-1 at the indicated concentration for 60min in the presence of 100nM Ex(9–39) (left panel) or JANT-4 (right panel) and the internalisation of hGLP-1R was assessed by ELISA (A) and immunofluorescence (C) using the anti-GLP-1R antibody. (B) The EC50 of GLP-1 in the presence or absence of Ex(9–39) or JANT-4 for hGLP-1R internalisation. In immunofluorescence, GFP-tag of hGLP-1R (green) and the anti-GLP-1R antibody staining (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean + SEM, n = 3, ** p<0.01; *** p <0.001.
Fig 5 Concentration dependent stimulation of hGLP-1R internalisation by GLP-1 in the presence of antagonists Ex(9–39) and JANT-4. HEK293 cells expressing the hGLP-1R were stimulated with GLP-1 at the indicated concentration for 60min in the presence of 100nM Ex(9–39) (left panel) or JANT-4 (right panel) and the internalisation of hGLP-1R was assessed by ELISA (A) and immunofluorescence (C) using the anti-GLP-1R antibody. (B) The EC50 of GLP-1 in the presence or absence of Ex(9–39) or JANT-4 for hGLP-1R internalisation. In immunofluorescence, GFP-tag of hGLP-1R (green) and the anti-GLP-1R antibody staining (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean + SEM, n = 3, ** p<0.01; *** p <0.001.CC BY · PubMed Central
Fig 6 Effect of V36A and K334A mutations of the hGLP1R on the receptor cell surface expression and activity. HEK293 cells were transfected with the hGLP-1R WT (wild-type) or the V36A or K334A mutants for 48h. (A) Total protein expression was assessed by immunoblotting using the anti-GFP and anti-VSVG antibodies. Cell surface expression (B) and agonist induced internalisation (C) were assessed by ELISA using the anti-GLP-1R antibody. (D) Immunofluorescence showing agonist induced internalisation of the WT or mutant hGLP-1R, GFP-tag of the constructs (green) and the anti-GLP-1R antibody staining (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean + SEM, n = 3, n.s. p<0.05; *** p <0.001.
Fig 6 Effect of V36A and K334A mutations of the hGLP1R on the receptor cell surface expression and activity. HEK293 cells were transfected with the hGLP-1R WT (wild-type) or the V36A or K334A mutants for 48h. (A) Total protein expression was assessed by immunoblotting using the anti-GFP and anti-VSVG antibodies. Cell surface expression (B) and agonist induced internalisation (C) were assessed by ELISA using the anti-GLP-1R antibody. (D) Immunofluorescence showing agonist induced internalisation of the WT or mutant hGLP-1R, GFP-tag of the constructs (green) and the anti-GLP-1R antibody staining (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean + SEM, n = 3, n.s. p<0.05; *** p <0.001.CC BY · PubMed Central
Fig 7 Effect of V36A and K334A mutations of the hGLP-1R on the receptor induced cAMP production. HEK293 cells cotransfected with the V36A (left panel) or K334A (right panel) hGLP-1R plasmid and the luciferase reporter plasmid for cAMP (pGL4.29-Luc-CRE) were stimulated with GLP-1 (A), compound 2 (B) or compound B (C) as indicated to assess cAMP production. (D) The EC50 of GLP-1, compounds 2 and B for cAMP production in cells expressing hGLP-1R WT or V36A or K334A (n.d., not determined). Data are mean ± SEM, n = 3, * p<0.05; ** p<0.01; *** p <0.001.
Fig 7 Effect of V36A and K334A mutations of the hGLP-1R on the receptor induced cAMP production. HEK293 cells cotransfected with the V36A (left panel) or K334A (right panel) hGLP-1R plasmid and the luciferase reporter plasmid for cAMP (pGL4.29-Luc-CRE) were stimulated with GLP-1 (A), compound 2 (B) or compound B (C) as indicated to assess cAMP production. (D) The EC50 of GLP-1, compounds 2 and B for cAMP production in cells expressing hGLP-1R WT or V36A or K334A (n.d., not determined). Data are mean ± SEM, n = 3, * p<0.05; ** p<0.01; *** p <0.001.CC BY · PubMed Central
Fig 8 Compounds 2 and B reduce the hGLP-1R internalisation by GLP-1. HEK293 cells expressing the hGLP-1R were pre-incubated with either 10μM compound 2 or B for 60min and then stimulated with GLP-1 at the indicated concentration for a further 60min in the presence of 10μM compound 2 (left panel) or compound B (right panel) and hGLP-1R internalisation was assessed by ELISA (A) and immunofluorescence (B) using the anti-GLP-1R antibody. In immunofluorescence, GFP-tag of hGLP-1R (green) and the anti-GLP-1R antibody staining (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean ± SEM, n = 3, *** p <0.001.
Fig 8 Compounds 2 and B reduce the hGLP-1R internalisation by GLP-1. HEK293 cells expressing the hGLP-1R were pre-incubated with either 10μM compound 2 or B for 60min and then stimulated with GLP-1 at the indicated concentration for a further 60min in the presence of 10μM compound 2 (left panel) or compound B (right panel) and hGLP-1R internalisation was assessed by ELISA (A) and immunofluorescence (B) using the anti-GLP-1R antibody. In immunofluorescence, GFP-tag of hGLP-1R (green) and the anti-GLP-1R antibody staining (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean ± SEM, n = 3, *** p <0.001.CC BY · PubMed Central
Fig 9 Compounds 2 and B reduce GLP-1 stimulated intracellular Ca2+ accumulation and ERK phosphorylation in hGLP-1R expressing cells. HEK293 cells cotransfected with the hGLP-1R plasmid and the luciferase reporter plasmid for cAMP (pGL4.29-Luc-CRE), intracellular Ca2+ (pGL4.30-Luc-NFAT) or ERK phosphorylation (pGL4.33-Luc-SRE) were pre-incubated with either 10μM compound 2 or B for 60min. Cells were then stimulated with GLP-1 at the indicated concentrations in the presence of 10μM compound 2 (left panel) or compound B (right panel) to assess cAMP production (A), intracellular Ca2+ accumulation (B) and ERK phosphorylation (C). Data normalised to percentage stimulation of GLP-1 and are shown as mean ± SEM, n = 3 (n.s. p>0.05; *** p <0.001).
Fig 9 Compounds 2 and B reduce GLP-1 stimulated intracellular Ca2+ accumulation and ERK phosphorylation in hGLP-1R expressing cells. HEK293 cells cotransfected with the hGLP-1R plasmid and the luciferase reporter plasmid for cAMP (pGL4.29-Luc-CRE), intracellular Ca2+ (pGL4.30-Luc-NFAT) or ERK phosphorylation (pGL4.33-Luc-SRE) were pre-incubated with either 10μM compound 2 or B for 60min. Cells were then stimulated with GLP-1 at the indicated concentrations in the presence of 10μM compound 2 (left panel) or compound B (right panel) to assess cAMP production (A), intracellular Ca2+ accumulation (B) and ERK phosphorylation (C). Data normalised to percentage stimulation of GLP-1 and are shown as mean ± SEM, n = 3 (n.s. p>0.05; *** p <0.001).CC BY · PubMed Central
Fig 10 Schematic representation of the downstream signalling pathways activated by GLP-1 and small molecule agonist compounds 2 and B deduced from this study (Ca2+i, intracellular Ca2+ accumulation).
Fig 10 Schematic representation of the downstream signalling pathways activated by GLP-1 and small molecule agonist compounds 2 and B deduced from this study (Ca2+i, intracellular Ca2+ accumulation).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 19

Metadata

Authors
Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V.
Affiliations
Swansea University (GB)
Corresponding author
Kanamarlapudi, Venkateswarlu
Venue
PLOS ONE
Published
2016-04-21
Volume
11
Issue
4
Pages
e0154229
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2341529564
Cited by
19
References
48
Citations by year
2024: 3 · 2023: 3 · 2021: 6 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 1
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Biotechnology and Biological Sciences Research Council (BB/F017596/1, BB/C515455/2)
  • Medical Research Council (G0401232)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
GLP-1 receptor, GLP-1 receptor agonists, receptor internalization, G protein-coupled receptor signaling, cAMP production, intracellular calcium accumulation, ERK1/2 phosphorylation, orthosteric binding site, receptor conformational change, small molecule agonists
MeSH terms
Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Cyclic AMP, Binding Sites, Calcium, Endocytosis, Humans, Mutation, Peptide Fragments, Peptides, Phosphorylation, Venoms, Immunoblotting, Signal Transduction, Microscopy, Confocal, Intracellular Space, Extracellular Signal-Regulated MAP Kinases, Glucagon-Like Peptide 1, Small Molecule Libraries, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation. https://app.cochat.ai/papers/10.1371/journal.pone.0154229
The paper
Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V. (2016). Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation. PLOS ONE. https://doi.org/10.1371/journal.pone.0154229

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.